

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

Purified anti-human CD134 (OX40) (Maxpar(R) Ready)

RRID:AB_2563718

Type: Antibody

Proper Citation

BioLegend Cat# 350015, RRID:AB_2563718

Antibody Information

URL: http://antibodyregistry.org/AB_2563718

Proper Citation: BioLegend Cat# 350015, RRID:AB_2563718

Target Antigen: CD134

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF®

Antibody Name: Purified anti-human CD134 (OX40) (Maxpar(R) Ready)

Description: This monoclonal targets CD134

Target Organism: human

Clone ID: Clone Ber-ACT35 (ACT35)

Antibody ID: AB_2563718

Vendor: BioLegend

Catalog Number: 350015

Record Creation Time: 20250819T231053+0000

Record Last Update: 20250820T043245+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD134 (OX40) (Maxpar(R) Ready).

No alerts have been found for Purified anti-human CD134 (OX40) (Maxpar(R) Ready).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Evangelista BA, et al. (2025) ALS-associated TDP-43 aggregates drive innate and adaptive immune cell activation. iScience, 28(6), 112648.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer cell, 41(5), 837.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer cell, 39(12), 1623.

Gide TN, et al. (2019) Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer cell, 35(2), 238.